Ultragenyx Pharmaceutical Inc. | Key People and Executives
Emil D. Kakkis
President, Chief Executive Officer & Director
Daniel G. Welch
Non-Executive Chairman
Michael A. Narachi
Independent Director
Clay B. Siegall
Independent Director
Matthew K. Fust
Independent Director
William E. Aliski
Independent Director
Emil D. Kakkis
President, Chief Executive Officer & Director
Shalini Sharp
Chief Financial Officer & Executive Vice President
Dennis Karl Huang
Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian
Chief Medical Officer & Executive Vice President
Javier San Martin
Vice President-Global Clinical Development
John Richard Pinion
Chief Quality Operations Officer & SVP-Research
Thomas Richard Kassberg
Chief Business Officer & Executive Vice President
Alison Skrinar
Senior Director-Clinical Sciences
Vimal Srivastava
Vice President-Program Development
Cordelia Leonard
Vice President-Regulatory Affairs
Theodore A. Huizenga
Principal Accounting Officer, Controller & VP
Danielle Bertrand
Head-IR & Corporate Communications
Karah Parschauer
Executive Vice President & General Counsel
Daniel G. Welch
Non-Executive Chairman
Deborah L. Dunsire
Independent Director
Lars G. Ekman
Independent Director
Michael A. Narachi
Independent Director
Clay B. Siegall
Independent Director
Matthew K. Fust
Independent Director
William E. Aliski
Independent Director
| Address |
60 Leveroni Court
Novato California 94949
United States
|
|
Employees
|
- |
| Website |
http://www.ultragenyx.com |
| Updated |
07/08/2019 |
| Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. |
